Evidence map›Paper›PMID 39974814›Full record

ArticleTranslational andrology and urology2025

Pathologic characteristics and management strategies for two categories of prostate cancer patients with low prostate-specific antigen undergoing radical prostatectomy.

Jiyuan Sun, Shu Gao, Xinwu Wang, Zhiyuan Yang, Jingxian Xu, Zhen Jiang, Yifan Sun, Xinping Wang, Hongqian Guo, Qing Zhang

Abstract read
In one paragraph

Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jiyuan Sun *Department of Urology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Shu Gao *Department of Urology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Xinwu Wang *Department of Urology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Zhiyuan YangDepartment of Urology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Jingxian XuDepartment of Urology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Zhen JiangDepartment of Urology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Yifan SunDepartment of Urology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Xinping WangMedical School of Southeast University Nanjing Drum Tower Hospital, Nanjing, China.
Hongqian Guo *Department of Urology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Qing Zhang *Department of Urology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Prostate cancer (PCa) with low levels of prostate-specific antigen (PSA) (0-4 ng/mL) includes PCa detected through biopsy and incidental PCa (IPC) in patients with previous prostate surgeries. The study was conducted to compare these two groups of patients undergoing radical prostatectomy (RP), aiming to assess pathological characteristics and suggest strategies for predicting and managing low PSA PCa. Methods: A retrospective analysis was performed on two categories of low PSA PCa patients. Baseline characteristics, PSA density (PSAD), preoperative multiparametric magnetic resonance imaging (mpMRI) for RP, preoperative and postoperative pathological data, and biochemical recurrence (BCR) were evaluated. Results: Fifty patients were analyzed. There were 80% of tumors being clinically significant and in early-stage, indicating a favorable prognosis for most low PSA PCa patients, and the use of preoperative androgen deprivation therapy (ADT) treatment may be beneficial for a small subset of patients with advanced tumors. Patients with low PSA and IPC history had lower PSA levels, PSAD, and prostate volume, however, BCR rates did not significantly differ between low PSA patients with and without IPC history. mpMRI and PSAD demonstrated potential in predicting PCa in low PSA cases. Conclusions: Predicting low PSA PCa remains challenging, but mpMRI and PSAD could be valuable predictors. Both low PSA groups showed a likelihood of clinical significance, with favorable pathological features. Early diagnosis and treatment are crucial, especially for aggressive IPC PCa tumors. Reevaluating PSA thresholds is vital to avoid missed or misdiagnosed low PSA cases.

Indexed as

incidental prostate cancer (IPC)pathologyProstate cancer (PCa)prostate-specific antigen (PSA)radical prostatectomy (RP)

Identifiers

PMID39974814
PMCPMC11833536

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.